Literature DB >> 20182403

Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema.

Clécio Takata1, Andre Messias, Marco S Folgosa, Levy R Lucena, Daniel R Lucena, Ingrid U Scott, Rodrigo Jorge.   

Abstract

PURPOSE: The purpose of this study was to compare the effectiveness of intravitreal injection (IVT) versus posterior subtenon infusion (STI) of triamcinolone acetonide performed during phacoemulsification cataract surgery in eyes with refractory diffuse diabetic macular edema.
METHODS: Twenty-four eyes of 24 patients with refractory diffuse diabetic macular edema scheduled to undergo phacoemulsification cataract surgery were randomly assigned to receive either a 4-mg IVT (n = 12) or a 40-mg STI (n = 12) of triamcinolone acetonide during cataract surgery. Comprehensive ophthalmic evaluation, including best-corrected visual acuity, intraocular pressure, and central macular thickness measured with optical coherence tomography, was performed at baseline and at 1, 4, 8 +/- 1, 12 +/- 2, and 24 +/- 2 weeks postoperatively.
RESULTS: Ten patients from the IVT group and 9 patients from the STI group completed the 24-week study visit. Mean baseline best-corrected visual acuity (logarithm of the minimum angle of resolution) was 20/259 and 20/222 in the IVT and STI groups, respectively (t = 0.41; P = 0.3407). A significant improvement in best-corrected visual acuity was observed only in the IVT group at 4 weeks (mean difference +/- standard error, improved to 20/116; P = 0.0437), 8 weeks (20/110; P = 0.0355), and 12 weeks (20/121; P = 0.0471) postoperatively. There was no significant change from baseline in mean intraocular pressure in either group. Mean +/- standard error baseline central macular thickness was 474.1 +/- 42.4 microm and 490.8 +/- 70.8 microm in the IVT and STI groups, respectively (t = 0.21; P = 0.5807). The central macular thickness reductions after surgery at all study follow-up visits were significantly greater in the IVT group than in the STI group (P < 0.05).
CONCLUSION: These data suggest that IVT is more effective than STI of triamcinolone acetonide for the management of refractory diffuse diabetic macular edema in eyes undergoing phacoemulsification. Further investigation of a larger number of patients with longer follow-up is necessary to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182403     DOI: 10.1097/IAE.0b013e3181c969b4

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Comparative study on pharmacokinetics and toxicity of intravitreal and sub-Tenon injection of triamcinolone acetonide in ocular tissues.

Authors:  Yuko Arie; Hiroko Miyai; Ayako Suzuki; Takeshi Okabe; Mitsuyo Takashima; Mayumi Takata; Takashi Kurasawa; Masaki Ito; Reijiro Arakawa; Yuichiro Ogura; Akira Naito
Journal:  Int J Ophthalmol       Date:  2020-12-18       Impact factor: 1.779

Review 2.  Analysis of Funding Source and Spin in the Reporting of Studies of Intravitreal Corticosteroid Therapy for Diabetic Macular Edema: A Systematic Review.

Authors:  Harrish Nithianandan; Ajay E Kuriyan; Michael J Venincasa; Jayanth Sridhar
Journal:  Clin Ophthalmol       Date:  2020-08-20

3.  Prophylactic interventions for preventing macular edema after cataract surgery in patients with diabetes: A Bayesian network meta-analysis of randomized controlled trials.

Authors:  Ruiheng Zhang; Li Dong; Qiong Yang; Yueming Liu; Heyan Li; Wenda Zhou; Haotian Wu; Yifan Li; Yitong Li; Chuyao Yu; Wenbin Wei
Journal:  EClinicalMedicine       Date:  2022-05-20

Review 4.  Adjuvant treatment modalities to control macular edema in diabetic patients undergoing cataract surgery.

Authors:  Ebru Nevin Cetin; Cem Yıldırım
Journal:  Int Ophthalmol       Date:  2012-12-18       Impact factor: 2.031

5.  Diabetic retinopathy - An update.

Authors:  Abdulrahman A Alghadyan
Journal:  Saudi J Ophthalmol       Date:  2011-01-31

Review 6.  Clinical trials on corticosteroids for diabetic macular edema.

Authors:  Hassan A Al Dhibi; J Fernando Arevalo
Journal:  World J Diabetes       Date:  2013-12-15

Review 7.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

8.  Effect of In Vitro Exposure of Corticosteroid Drugs, Conventionally Used in AMD Treatment, on Mesenchymal Stem Cells.

Authors:  Raffaele Nuzzi; Monica Gunetti; Deborah Rustichelli; Barbara Roagna; Francesca Fronticelli Bardelli; Franca Fagioli; Ivana Ferrero
Journal:  Stem Cells Int       Date:  2012-05-23       Impact factor: 5.443

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.